Interconnecting diagnostic progress and management techniques in depression: A narrative review

Major depressive disorder remains a leading cause of disability worldwide and continues to produce substantial personal, social, and economic burden. This narrative review critically examines recent progress in depression diagnosis and management, emphasizing the connection between diagnostic precision and treatment selection. Current diagnosis still depends on clinical assessment and validated rating scales, while biomarkers, neuroimaging, electroencephalography, digital phenotyping, and microbiome research remain promising but insufficiently validated as stand-alone diagnostic tools. Management has also evolved beyond first-line antidepressants and psychotherapy toward measurement-based care, augmentation strategies, somatic therapies, home-based neuromodulation, esketamine, ketamine, neuroactive steroids, glutamatergic agents, and carefully supervised psychedelic-assisted models. However, most emerging approaches face limitations related to cost, accessibility, long-term safety, implementation burden, and generalizability across populations. The review also addresses stigma, disparities between high-income and low- and middle-income settings, treatment-resistant depression, and personalized medicine. A clinically useful roadmap should integrate symptom profiles, comorbidity, patient preference, pharmacogenomics, biomarkers, digital measures, and longitudinal treatment response. Depression care is therefore moving from a single-modality model toward a coordinated, evidence-informed, and patient-centered framework in which diagnostic advances guide safer and more individualized management.